However, there remains an urgent need for a high-quality, large-sample, randomized controlled trial to establish the efficacy and safety of CHM as an adjuvant therapy in combination with chemotherapy for NSCLC patients who have developed resistance to EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.